← All trials
NCT02431806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2015
- Primary completion
- Dec 21, 2018
- Completion date
- Dec 21, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 660
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Forest LaboratoriesLead sponsor
- AllerganStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.